Blog
RSS FeedPosted by Michael Wonder on 28 May 2021
U.S. Food and Drug Administration approves Bristol Myers Squibb’s Zeposia (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis
27 May 2021 - Bristol Myers Squibb is committed to making Zeposia accessible to appropriate patients who need it through the ...
Posted by Michael Wonder on 28 May 2021
Tagrisso approved in the EU for the adjuvant treatment of patients with early stage EGFR mutated lung cancer
28 May 2021 - Approval based on unprecedented results from the ADAURA Phase 3 trial where Tagrisso reduced the risk ...
Posted by Michael Wonder on 28 May 2021
Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
25 May 2021 - Novartis today announced that the US FDA has granted fast track designation for sabatolimab (MBG453) for the ...
Posted by Michael Wonder on 28 May 2021
Post-market review of opiate dependence treatment program medicines
28 May 2021 - On 24 March 2021 it was announced the Department of Health will conduct a post-market review ...
Posted by Michael Wonder on 27 May 2021
Amazon looking at opening pharmacy stores in US
26 May 2021 - Amazon is considering the launch of brick and mortar pharmacies in the United States, Insider reported ...
Posted by Michael Wonder on 27 May 2021
NASP applauds the Introduction of bipartisan legislation to reduce drug costs and support medication access for seniors with life-threatening specialised conditions
27 May 2021 - This week, a bipartisan group of lawmakers in the U.S. House and Senate introduced legislation to rein ...
Posted by Michael Wonder on 27 May 2021
Insufficient data on use of inhaled corticosteroids to treat COVID-19
27 May 2021 - EMA’s COVID-19 taskforce is advising health care professionals that there is currently insufficient evidence that inhaled ...
Posted by Michael Wonder on 27 May 2021
Democrats promised to lower drug prices, but plans are sputtering
26 May 2021 - With control of Congress and the White House, Democrats have an opportunity to bring down prescription ...
Posted by Michael Wonder on 27 May 2021
FDA approves Biohaven's Nurtec ODT (rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
27 May 2021 - Nurtec ODT 75 mg is the first oral CGRP antagonist approved to prevent migraine. ...
Posted by Michael Wonder on 27 May 2021
'Anticancer drug should extend life for 22 months to get insurance benefits'
27 May 2021 - A research team at National Cancer Center has found that the public believes that for an ...
Posted by Michael Wonder on 27 May 2021
7 out of 10 Koreans want cheaper drug with same ingredient
27 May 2021 - Seven out of 10 Koreans want to lower the drug cost by choosing a cheaper generic ...
Posted by Michael Wonder on 27 May 2021
Foresee Pharmaceuticals announces FDA approval of Camcevi for the treatment of advanced prostate cancer; Accord BioPharma to head the U.S. commercialisation
26 May 2021 - Foresee Pharmaceuticals announced today that the U.S. FDA has approved the new drug application for Camcevi 42 ...
Posted by Michael Wonder on 27 May 2021
FDA authorises additional monoclonal antibody for treatment of COVID-19
26 May 2021 - Today, the U.S. FDA issued an emergency use authorisation for the investigational monoclonal antibody therapy sotrovimab for ...
Posted by Michael Wonder on 27 May 2021
Mezzion's new drug application for its orphan drug udenafil for the treatment of single ventricle heart disease has been accepted for filing by the FDA
25 May 2021 - Mezzion Pharma is pleased to announce today that it has received notice from the FDA that ...
Posted by Michael Wonder on 26 May 2021
Prime Therapeutics launches MedDrive, a first of its kind medical drug management program uniquely aligned with its Blue Plan clients
26 May 2021 - MedDrive to tackle the toughest challenges facing growing medical Rx drug spend, harness the multi-billion dollar potential ...